How M.D. was paid
$2.9M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Other | Total |
|---|---|---|---|---|---|
| Lindsay A. Rosenwald, M.D.Executive Chairman, Chief Executive Officer and President | $62,665 | $500,000 | $2,199,592 | $125,000 | $2,887,256 |
| David JinChief Financial Officer and Head of Corporate Development | $427,875 | $172,200 | — | $64,000 | $664,075 |
| Michael S. WeissExecutive Vice Chairman, Strategic Development | $62,665 | $500,000 | $1,789,096 | $90,000 | $2,441,762 |
What changed and why
- $2.9MCEO total compensation increased to $2,887,256 in 2025 from $1,380,197 in 2024.
- $500KDr. Rosenwald received a $500,000 bonus and $2,199,592 in stock awards for 2025.
- $62,665Dr. Rosenwald and Mr. Weiss elected to largely forego base salary, receiving $62,665 each.
- $664KCFO David Jin received total compensation of $664,075, down from $2,565,267 in 2024.
- LTIP participants were each awarded 475,163 restricted common shares for performance in 2025.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.